logo

For the Inventor, By the Inventor

Portage, MI, United States of America

Ronald B Gammill

This inventor holds 33 USPTO granted patents, primarily in Antiatherosclerotic Compounds. Top assignees: The Upjohn Co., Pharmacia & Upjohn Company. Active years: 1981-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald B Gammill. Retrieved from https://idiyas.com/inventor/ronald-b-gammill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33

% Patents Active = 100.0

Average Co-Inventor Count = 1.4

ph-index = 10

Forward Citations = 334(Granted Patents)


Location History:

  • Kalamazoo, MI (US) (1992 - 1997)
  • Portage, MI (US) (1981 - 2001)

Company Filing History:

goldMedal28 out of 2,170 
 
The Upjohn Co.
 patents
silverMedal5 out of 523 
 
Pharmacia & Upjohn Company
 patents

Years Active: 1981-2001

Loading Chart...
Areas of Expertise:
Retroviral Infections
Pyranone Compounds
Benzopyran
Oxazolidinone Antimicrobials
Quinolone Compounds
Furochromones
Bivalent Ligands
Peptides
Atherosclerosis
Synthetic Routes
Antibacterial Agents
Diazine Moieties
33 patents (USPTO):Explore Patents
1. 6169181 - Compounds useful to treat retroviral infections (2001-01-02),
2. 5852195 - Pyranone compounds useful to treat retroviral infections (1998-12-22),
3. 5703075 - Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and (1997-12-30),
4. 5700799 - Oxazolidinone antimicrobials containing substituted diazine moieties (1997-12-23),
5. 5686486 - 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl�b!pyran-2-ones (1997-11-11),
6. 5610158 - 4-oxo- and 4H-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine (1997-03-11),
7. 5547950 - Oxazolidinone antimicrobials containing substituted diazine moieties (1996-08-20),
8. 5541324 - Imidazo[1,5-A]quinoxalines (1996-07-30),
9. 5385906 - Antibacterial quinolone compounds (1995-01-31),
10. 5304548 - Bivalent ligands effective for blocking ACAT enzyme for lowering plasma (1994-04-19),
11. 5262417 - Antibacterial quinolone compounds (1993-11-16),
12. 5180717 - Bivalent ligands effective for blocking ACAT enzyme for lowering plasma (1993-01-19),
13. 5132400 - Peptides containing a (1-amino-2-hydroxy-2-heterocyclic)ethyl moiety (1992-07-21),
14. 4820851 - Intermediates for antiatherosclerotic furochromones (1989-04-11),
15. 4614809 - Antiatherosclerotic furochromones and intermediates therefor (1986-09-30),

Title: Innovations and Contributions of Ronald B. Gammill in Retroviral Treatment

Introduction

Ronald B. Gammill is an esteemed inventor based in Portage, MI, recognized for his significant contributions to the field of pharmaceuticals, particularly in the treatment of retroviral infections. Throughout his career, he has been granted a total of 33 patents, showcasing his commitment to innovation and advancement in medical science.

Latest Patents

Among his notable patents, Ronald's recent inventions include compounds designed to treat retroviral infections. His patent on "Compounds Useful to Treat Retroviral Infections" details compounds of formula I and II, which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, and other derivatives. These compounds have demonstrated the potential for inhibiting retroviruses in mammalian cells infected with said retroviruses. Additionally, he has developed "Pyranone Compounds Useful to Treat Retroviral Infections," further extending the scope of therapeutic options to combat these challenging infections.

Career Highlights

Ronald Gammill has had a prolific career, with significant roles at well-known companies, including The Upjohn Company and Pharmacia & Upjohn Company. His work has spanned several decades, during which he has focused intensively on the pharmaceutical applications of his inventions, contributing to advancements in healthcare and medication efficacy.

Collaborations

Throughout his career, Ronald has collaborated with notable colleagues such as Michael R. Barbachyn and Thomas M. Judge. These collaborations have enriched his research and propelled further innovations in the pharmaceutical industry.

Conclusion

In summary, Ronald B. Gammill's inventive spirit and dedication to research have led to substantial advancements in the treatment of retroviral infections. His patents not only reflect his innovative approach but also represent a significant contribution to the medical community, improving outcomes for patients affected by retroviral diseases. The impact of his work continues to be felt in the realms of research and pharmacology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…